The Effectiveness and Efficacy of the Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective for Patients With Mental Health Disorders
NCT: NCT06993662 ·
Status: ACTIVE NOT RECRUITING ·
Phase: Phase 1
· Sponsor: Rakitzi, Stavroula
· Started: 2025-06-02
· Est. Completion: 2027-12-20
Official Summary
The combination of pharmacotherapy and individual cognitive behavioral therapy in a private practice.
Study Design
- Study Type: INTERVENTIONAL
- Allocation: NON_RANDOMIZED
- Model: PARALLEL
- Masking: SINGLE
- Enrollment: 107 participants
Interventions
- COMBINATION_PRODUCT: Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression. — The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI) and individual cognitive behavioral psychotherapy by anxiety disorders and depression.
- COMBINATION_PRODUCT: Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD — The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI) and individual cognitive behavioral psychotherapy by PTSD
- COMBINATION_PRODUCT: Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder. — The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.
- COMBINATION_PRODUCT: Group D.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by bipolar disorder — The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil) antidepressants (SSRI, SNRI), mood stabilizers (lithium, depakine), antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by bipolar disorder.
- COMBINATION_PRODUCT: Group E. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders — The combination of pharmacotherapy (anxiolytics(tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI), antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders.
Primary Outcomes
- MCCB BACS symbol coding (Preintervention)
- MCCB BACS symbol coding (Immediately after the intervention)
- MCCB BACS symbol coding (Follow-up up to 24 weeks)
- MCCB Wechsler memory scale-spatial span (Preintervention)
- MCCB Wechsler memory scale-spatial span (Immediately after the intervention)
Secondary Outcomes
- WAIS (Preintervention)
Trial Locations
- Private practice of Dr. S. Rakitzi and Dr. P. Georgila ILISION 34 15771 ATHENS GREECE, Athens, Greece
More Anxiety Trials
AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.